Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies

BACKGROUND/AIMS: To evaluate intravitreal aflibercept versus laser in subgroups of patients with baseline Diabetic Retinopathy Severity Scale (DRSS) scores ≤43, 47, and ≥53 in VIVID-DME and VISTA-DME. METHODS: Patients with diabetic macular oedema were randomised to receive intravitreal aflibercept...

Descripción completa

Detalles Bibliográficos
Autores principales: Staurenghi, Giovanni, Feltgen, Nicolas, Arnold, Jennifer J, Katz, Todd A, Metzig, Carola, Lu, Chengxing, Holz, Frank G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047149/
https://www.ncbi.nlm.nih.gov/pubmed/29051325
http://dx.doi.org/10.1136/bjophthalmol-2017-310664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047149/
https://www.ncbi.nlm.nih.gov/pubmed/29051325
http://dx.doi.org/10.1136/bjophthalmol-2017-310664

Ejemplares similares